SCHEMBL4670285

SCHEMBL4670285

COc1ccc(C(OCCOC(c2ccccc2)c2ccc(OC)cc2)c2ccccc2)cc1

nearest known ligand 0.57

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN1A P35498 3/20 0.55
SCN2A Q99250 3/20 0.55
SCN3A Q9NY46 3/20 0.55
LMNA P02545 2/20 0.55
CHRM2 P08172 2/20 0.55
ADRA2A P08913 2/20 0.55
CHRM1 P11229 2/20 0.55
SLC6A2 P23975 2/20 0.55
SLC6A4 P31645 2/20 0.55
OPRM1 P35372 2/20 0.55
DRD3 P35462 2/20 0.55
HTT P42858 2/20 0.55
SLC6A3 Q01959 2/20 0.55
CYP1A2 P05177 1/20 0.55
CHRM4 P08173 1/20 0.55
CHRM5 P08912 1/20 0.55
CYP2D6 P10635 1/20 0.55
TSHR P16473 1/20 0.55
ADRA2B P18089 1/20 0.55
CHRM3 P20309 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4669215 0.90 ACP3 (0.50) SCN1ASCN2ASCN3ALMNACHRM2
Medrylamine SCHEMBL142910 0.87 SLC6A2 (0.78) SCN1ASCN2ASCN3ALMNACHRM2
SCHEMBL4667564 0.83 SCN1A (0.65) SCN1ASCN2ASCN3ALMNACHRM2
SCHEMBL17599983 0.82 ACP3 (0.56) TSHRMAPK1LTA4HACP3PBRM1
SCHEMBL78901 0.82 ACP3 (0.56) TSHRMAPK1LTA4HACP3PBRM1
SCHEMBL13705512 0.82 TDP1 (0.54) CHRM2ADRA2ACHRM1SLC6A2SLC6A4
SCHEMBL3932308 0.81 LTA4H (0.58) FFAR1LTA4H
SCHEMBL8290695 0.81 MMP3 (0.52) OPRM1CYP1A2CYP2D6TSHRSMN1; SMN2
SCHEMBL4668992 0.80 SCN1A (0.58) SCN1ASCN2ASCN3ALMNACHRM2
SCHEMBL11784757 0.78 ACP3 (0.58) LTA4HACP3PBRM1CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1930308-A1 Pharmaceutical agents for the treatment of cerebral amyloidosis NYMOX CORPORATION (CA) 2008-06-11 EP disclosed
EP-0983222-B1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 2007-11-28 EP disclosed
EP-0983222-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 2000-03-08 EP disclosed
WO-1998052898-A9 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORP (CA) 1999-04-01 WO disclosed
WO-1998052898-A1 PHARMACEUTICAL AGENTS FOR THE TREATMENT OF CEREBRAL AMYLOIDOSIS NYMOX CORPORATION (CA) 1998-11-26 WO disclosed